Kinase News and Research

RSS

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

TSRI chemists identify and design potent therapeutic ‘warheads’ for different diseases

In a pair of related studies, chemists from the Florida campus of The Scripps Research Institute (TSRI) have identified and designed dozens of molecular “warheads” that not only can detect a key biomarker of cancer, but also could be developed into a potent new class of drug candidates for a range of diseases.

13 May 2016

Genetic variations that increase PKC alpha activity may influence development of Alzheimer's disease

In Alzheimer's disease, plaques of amyloid beta protein accumulate in the brain, damaging connections between neurons.

11 May 2016

New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

Obstetricians and midwives are today welcoming the publication of new NICE guidance recommending the use of a new test from Roche Diagnostics that can rule-out the development of the life threatening condition, pre-eclampsia, within one week in pregnant women.

11 May 2016

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

The Medical University of South Carolina's Hollings Cancer Center received an $8.9 million grant from the National Cancer Institute designed to foster collaboration across clinical and laboratory research for the study of signaling in sphingolipids, a class of lipids known to be involved in the growth of solid tumor cancers.

10 May 2016

LJI study could provide important target for autoimmune disease interventions

Follicular helper T cells (Tfh cells), a rare type of T cells, are indispensable for the maturation of antibody-producing B cells. They promote the proliferation of B cells that produce highly selective antibodies against invading pathogens while weeding out those that generate potentially harmful ones.

3 May 2016

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics.

3 May 2016

Newly identified molecular pathway could lead to new treatments for reflux, incontinence disorders

Researchers at UMass Medical School have identified a new molecular pathway critical for maintaining the smooth muscle tone that allows the passage of materials through the digestive system.

25 Apr 2016

Novel function of PLK1 gene in prostate cancer metastasis

Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1's role in cancer growth and progression.

22 Apr 2016

GSK3β inhibition may be potential therapeutic strategy for treating ACM

Arrhythmogenic cardiomyopathy (ACM) is an inherited heart disease that results from mutations in genes that encode components of the cardiac desmosome, which forms the junction between cardiac muscle and the epithelium. Patients with ACM have an increased risk of sudden death due to the breakdown of the muscle wall of the heart with age.

22 Apr 2016

BCR-ABL halving time indicates CML prognosis during front-line TKI

Calculating halving time of the BCR-ABL transcript after 3 months may help determine prognosis in chronic myeloid leukaemia patients undergoing first-line tyrosine kinase inhibitor therapy, say researchers.

21 Apr 2016

Bosutinib shows 'low' vascular, cardiac event risk profile

Third-generation tyrosine kinase inhibitor study findings suggest that bosutinib is associated with a low risk of vascular and cardiac events in patients undergoing first-line or subsequent treatment for chronic myeloid leukaemia.

21 Apr 2016

Vegetable-based polyphenol enhances wound healing

A research group led by Osaka University found a plant-based polyphenol, promotes the migration of Mesenchymal Stem Cells (MSCs) in blood circulation and accumulates them in damaged tissues to improve wound healing. It is anticipated that the results will be used for stem cell treatments for cutaneous disorders associated with various damage and lesions.

21 Apr 2016

Frontline nilotinib supported for newly diagnosed CP-CML

Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis.

21 Apr 2016

Pre-TKI cytokine profiling predicts CP-CML outcome

Measuring levels of transforming growth factor-α and interleukin-6 may help identify patients with newly diagnosed chronic phase-chronic myeloid leukaemia at risk of a poor outcome from tyrosine kinase inhibitor therapy, research suggests.

20 Apr 2016

Additional chromosomal abnormalities prognostic for CML

Additional chromosomal abnormalities can be used to create two prognostic groups of patients with chronic myeloid leukaemia, suggests research published in Blood.

20 Apr 2016

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

If genes form the body's blueprint, then the layer of epigenetics decides which parts of the plan get built. Unfortunately, many cancers hijack epigenetics to modulate the expression of genes, thus promoting cancer growth and survival.

19 Apr 2016

Researchers identify biological pathway that explains why current asthma therapies fail in many cases

Asthma is an enormous public health problem that continues to grow larger, in part because scientists don't fully understand how it is caused. Existing therapies don't cure the disease and often don't even significantly alleviate the symptoms. Now, scientists from the Perelman School of Medicine at the University of Pennsylvania and Rutgers University have identified a biological pathway that potentially explains why current asthma therapies don't work well in many cases—and might be targeted to help those patients.

19 Apr 2016

Scientists discover new diagnostic marker for liver cancer

Scientists may have discovered a significant new diagnostic marker for liver cancer, according to a paper published in the April 18 online issue of Nature Cell Biology.

19 Apr 2016

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland. Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.

18 Apr 2016

Kinase News and Research

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

TSRI chemists identify and design potent therapeutic ‘warheads’ for different diseases

Genetic variations that increase PKC alpha activity may influence development of Alzheimer's disease

New NICE guidance recommends use of Roche Diagnostics’ new pre-eclampsia test

MUSC Hollings Cancer Center receives $8.9 million grant to explore signaling in sphingolipids

LJI study could provide important target for autoimmune disease interventions

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Newly identified molecular pathway could lead to new treatments for reflux, incontinence disorders

Novel function of PLK1 gene in prostate cancer metastasis

GSK3β inhibition may be potential therapeutic strategy for treating ACM

BCR-ABL halving time indicates CML prognosis during front-line TKI

Bosutinib shows 'low' vascular, cardiac event risk profile

Vegetable-based polyphenol enhances wound healing

Frontline nilotinib supported for newly diagnosed CP-CML

Pre-TKI cytokine profiling predicts CP-CML outcome

Additional chromosomal abnormalities prognostic for CML

Newly discovered player in epigenetic regulation closely linked to known cancer promoters

Researchers identify biological pathway that explains why current asthma therapies fail in many cases

Scientists discover new diagnostic marker for liver cancer

Studies confirm benefit of plasma genotyping to predict treatment outcomes for NSCLC patients

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News